Obesity and Cancer: An Angiogenic and Inflammatory Link.
Obesity and Cancer: An Angiogenic and Inflammatory Link.
复制标题
DOI：
10.1111/micc.12270
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
Jain RK
中科院分区：
文献类型：
--
作者：
Fukumura D;Incio J;Shankaraiah RC;Jain RK
随着目前肥胖的流行，大量被诊断为癌症的患者超重或肥胖。重要的是，这种超重与肿瘤进展和不良预后有关。然而，导致这种更糟糕结果的机制仍然知之甚少。我们回顾了肥胖和癌症之间关联的流行病学证据，并讨论了血管生成和炎症的潜在机制。特别是，我们将讨论肥胖患者脂肪组织中发生的功能失调的血管生成和炎症如何促进肿瘤进展、对化疗的抵抗以及抗血管生成和免疫治疗等靶向治疗。更好地了解肥胖是如何促进肿瘤进展和治疗抵抗的，对于提高目前的治疗标准和癌症患者的临床结果至关重要。为此，我们将讨论像二甲双胍这样的抗糖尿病药物如何克服肥胖对肿瘤进展和治疗耐药性的这些不利影响。
With the current epidemic of obesity, a large number of patients diagnosed with cancer are overweight or obese. Importantly, this excess body weight is associated with tumor progression and poor prognosis. The mechanisms for this worse outcome, however, remain poorly understood. We review here the epidemiological evidence for the association between obesity and cancer, and discuss potential mechanisms focusing on angiogenesis and inflammation. In particular, we will discuss how the dysfunctional angiogenesis and inflammation occurring in adipose tissue in obesity may promote tumor progression, resistance to chemotherapy, and targeted therapies such as anti-angiogenic and immune therapies. Better understanding of how obesity fuels tumor progression and therapy resistance is essential to improve the current standard of care and the clinical outcome of cancer patients. To this end, we will discuss how an anti-diabetic drug such as metformin can overcome these adverse effects of obesity on the progression and treatment resistance of tumors.